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PURPOSE: Treatment efficacy and toxicity are difficult to predict in lymphoma patients. In this study, the utility of circulating biomarkers
in predicting and/or monitoring treatment efficacy/toxicity were investigated.
PATIENTS AND METHODS: Circulating biomarkers of cell death (nucleosomal DNA (nDNA) and cytokeratin 18 (CK18)), and circulating
FLT3 ligand, a potential biomarker of myelosuppression, were assessed before and serially after standard chemotherapy in 49 patients
with Hodgkin and non-Hodgkin lymphoma. Cytokeratin 18 is not expressed in lymphoma cells so is a potential biomarker of epithelial
toxicity in this setting. Tumour response was assessed before and after completion of chemotherapy by 2D and 3D computed
tomography radiological response.
RESULTS: Baseline nDNA level was significantly higher in all lymphoma subtypes compared with 61 healthy controls and was prognostic
for progression-free survival in diffuse large B-cell lymphoma (DLBCL). Decreases in nDNA levels were observed in the first week
after chemotherapy; in FL, early falls in nDNA predicted for long remission following therapy. In DLBCL, elevations in nDNA
occurred in cases with progressive disease. Circulating CK18 increased within 48h of chemotherapy and was significantly higher in
patients experiencing epithelial toxicity graded 43 by Common Terminology for Classification of Adverse Events criteria. FLT3 ligand
was elevated within 3–8 days of chemotherapy initiation and predicted those patients who subsequently developed neutropenic
sepsis.
CONCLUSION: These data suggest circulating biomarkers contribute useful information regarding tumour response and toxicity in
patients receiving standard chemotherapy and have potential utility in the development of individualised treatment approaches in
lymphoma. These biomarkers are now being tested within multicentre phase III trials to progress their qualification.
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The majority of lymphomas are treatable and many, with modern
treatment approaches are potentially curable. There is, however,
a need to mitigate the risk of life-threatening treatment toxicity
and to overcome the poor prognosis associated with treatment
failure. This has led to interest in the development of biomarkers
that report the efficacy/toxicity of treatments and inform the
development of individualised treatment strategies. Tissue-based
biomarkers are the traditional ‘gold standards’ used in drug
development, but circulating biomarker analyses are more
readily applicable to most clinical settings. A biomarker detected
in the blood and measured serially could provide a real-time
assessment of a patient’s disease course and response to treatment
(Workman et al, 2006). Here, as a first step towards biomarker
qualification, a panel of circulating biomarkers of cell death and
myelosuppression has been evaluated for its potential to predict
and/or report drug efficacy and toxicity in patients with lymphoma
receiving standard chemotherapies.
During apoptosis, chromatin is cleaved into nucleosomal
strands by caspase-activated endonucleases (Oberhammer et al,
1993). Nucleosomes reside in membrane-bound apoptotic frag-
ments, undergo macrophage phagocytosis and are released into
the blood as nucleosomal DNA (nDNA) (Jiang et al, 2003).
Circulating nDNA levels are elevated in patients with cancer
including lymphoma (Deligezer et al, 2006) compared with healthy
controls, and have demonstrated prognostic and pharmaco-
dynamic utility in studies of lung cancer and other tumour types
(Holdenrieder et al, 2008; Hou et al, 2009). In this study of nDNA
in patients with lymphoma, we postulated that baseline nDNA
predicts treatment outcome and that changes in nDNA levels
during therapy act as pharmacodynamic and surrogate biomarkers
of response.
Cytokeratin 18 (CK18), a major component of an epithelial cell
cytoskeleton, is not expressed in cells of lymphoid origin.
Consequently, elevated circulating CK18 levels reflect epithelial
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sepsis, hepatitis and ischaemic heart disease (Adlbrecht et al, 2007;
Feldstein et al, 2009; Hofer et al, 2009). Here, we postulated that
circulating CK18 levels measured soon after initiating treatment
for lymphoma would be useful for monitoring and/or predicting
subsequent epithelial toxicity.
Myelosuppression and potentially life-threatening sepsis are
common complications of chemotherapy (Kuderer et al, 2007).
FLT3 ligand, a cytokine that binds the FLT3 receptor, acts
synergistically with other cytokines such as stem cell factor and
granulocyte colony-stimulating factor in the maintenance of the
stem cell compartment and in progenitor expansion/differentia-
tion during haematopoiesis. FLT3 ligand may be particularly
important in expansion of the stem cell compartment in response
to bone marrow stress (Buza-Vidas et al, 2007). In this study, we
postulated that changes in soluble FLT3 ligand in patients
receiving standard doses of chemotherapy would provide an early
warning of severe myelosuppression that could in future be used to
guide early intervention with growth factors.
In this study, we have evaluated the utility of nDNA to monitor
treatment response, CK18 to monitor and/or predict epithelial
toxicity and FLT3 ligand to monitor myelotoxicity in patients with
lymphoma receiving standard chemotherapy. This study was also
designed with a view to exploring the potential utility of these
circulating biomarkers in future clinical trials investigating
individualised treatment strategies.
PATIENTS AND METHODS
Patients and blood sample collection
The study received ethical approval from the North Manchester
Research Ethics Committee in December 2006 and was conducted
according to good clinical practice. Patients with a history of auto-
immune disease, viral hepatitis or HIV were excluded as these
conditions are known to be associated with high levels of the
biomarkers under investigation. Fifty patients with histologically
confirmed Hodgkin (HL), follicular (FL) or diffuse large B-cell
lymphoma (DLBCL) were recruited between 2007 and 2009 before
starting chemotherapy. One patient found to be ineligible after
consent was withdrawn. The clinical characteristics of the
remaining 49 patients are shown in Table 1. Patients had standard
clinical follow-up (median 479 days (range 10–748 days)).
Control samples were obtained from 61 healthy volunteers at a
single time-point. Blood samples were collected from lymphoma
patients on days 1, 3, 8 and 15 of the first treatment cycle and days
1 and 3 of subsequent cycles of chemotherapy (Figure 1). On
treatment days, samples were taken immediately before the
administration of chemotherapy. All samples for serum were
processed within 2h of collection as previously described and all
samples analysed within 3 months of collection. These conditions
have been shown not to have any significant effect on CK18 levels
(Greystoke et al, 2008).
Treatment
Patients were treated with standard chemotherapy according to
histological sub-type (Figure 1). Patients with HL were treated
with ABVD (doxorubicin 25mgm
–2, bleomycin 10000IU, vin-
blastine 6mgm
–2 and dacarbazine 375mgm
–2) every 14 days.
Patients with FL were treated with R-CVP (rituximab 375mgm
–2,
cyclophosphamide 750mgm
–2, vincristine 2mg and prednisone
40mgm
–2 (for 5 days)) every 21 days; in the event of insufficient
radiological or clinical response doxorubicin 50mgm
–2was added
to the regimen (n¼1). Patients with DLBCL were treated with
R-CHOP (rituximab 375mgm
–2, cyclophosphamide 750mgm
–2,
vincristine 2mg, doxorubicin 50mgm
–2 andprednisone40mgm
–2
(for 5 days)) every 21 days.
Circulating biomarkers
Serum was analysed for (a) nDNA using the Cell Death Detection
ELISA (Roche, Basel, Switzerland), (b) CK18 using the M65 ELISA
(Peviva, Sweden) and (c) FLT3 ligand using an ELISA (R&D,
Abingdon, UK; #DFK00). All analyses followed the manufacturer’s
instructions and were conducted according to Good Clinical
Laboratory Practice. As nDNA is a quasi-quantative ELISA, data
are expressed as optical density readings. The M65 and FLT3
ligand ELISAs are semi-quantative assays and data are expressed
in Ul
–1 and pgml
–1, respectively. Both full blood count and
lactate dehydrogenase (LDH) were determined independently by
the Christie Pathology Laboratories (Manchester, UK).
Table 1 Clinical characteristics of patients with Hodgkin lymphoma,
follicular lymphoma and diffuse large B-cell lymphoma
HL FL DLBCL
Number 13 10 26
Age (median (range)) 38 (18–61) 60 (47–85) 69 (22–90)
Gender male:
female (% male)
4:9 (31%) 5:5 (50%) 14:12 (54%)
PS
0 5 (38%) 4 (40%) 4 (15%)
1 7 (54%) 6 (60%) 16 (62%)
2 1(8%) 0 2 (8%)
3 0 0 4 (15%)
Stage
I 1 (8%) 0 4 (15%)
II 6 (46%) 2 (20%) 7 (27%)
III 2 (15%) 2 (20%) 3 (11%)
IV 4 (31%) 6 (60%) 12 (46%)
‘B’ symptoms 7 (54%) 0 13 (50%)
Therapy ABVD ( 3) 1 R-CVP 10
(two converted
to R-CHOP)
R-CHOP 24
(two converted
to R-GCVP)
ABVD ( 6) 12 R-GCVP 2
Abbreviations: ABVD¼therapy with doxorubicin, bleomycin, vinblastine and
dacarbazine; ‘B’ symptoms¼weight loss 410%, drenching night sweats or
unexplained fevers 4381C; DLBCL¼diffuse large B-cell lymphoma; FL¼follicular
lymphoma; HL¼Hodgkin lymphoma; PS¼performance status; stage¼as defined by
Ann-Arbor Staging System; R-CVP¼therapy with rituximab, cyclophosphamide,
vincristine and prednisone; R-CHOP¼therapy with rituximab, cyclophosphamide,
doxorubicin, vincristine and prednisone; R-GCVP¼therapy with rituximab,
gemcitabine, cyclophosphamide, vincristine and prednisone.
18 2 2 Day of
therapy
15
ABVD Cycle 2 ABVD ABVD
R-CVP R-CVP Cycle 2
29
R-CHOP Cycle 2 R-CHOP
X
Biomarker
analysis
Y Y X
Figure 1 Schedule of administration of anticancer agents and biomarker
analysis. X¼analysis performed every cycle, Y¼analysis performed first
cycle only (analysis on treatment days performed on samples taken before
therapy); ABVD, doxorubicin 25mgm
–2, bleomycin 10000IU, vinblastine
6mgm
–2 and dacarbazine 375mgm
–2 every 14 days. R-CVP, rituximab
375mgm
–2, cyclophosphamide 750mgm
–2, vincristine 2mg and pre-
dnisone 40mgm
–2 (for 5days) every 21 days. R-CHOP, rituximab
375mgm
–2, cyclophosphamide 750mgm
–2, vincristine 2mg, doxorubicin
50mgm
–2 and prednisone 40mgm
–2 (for 5 days) every 21 days.
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X-ray computed tomography (CT) examination was performed
before and after therapy. Patients were imaged on a LightSpeed
Plus CT scanner (GE Medical Systems, Slough, UK) with typical
clinical helical acquisition variables (tube voltage 120kV, tube
current 40mA). Images were acquired following intravenous
injection of 200ml Omnipaque-140 (GE Medical Systems) and
reformatted to produce contiguous slices with no overlap. Slice
thickness was 5mm in all but four cases, where initial data
constraints necessitated a slice thickness of 7.5mm. Nodal tumour
burden was assessed by measuring enlarged lymph nodes. Two
types of measurements were made based on (a) the sum of the
bi-dimensional measurements (units cm
2) as recommended in the
Cheson criteria (Cheson et al, 2007) and (b) tumour volume,
calculated as the product of the number of voxels and voxel
volume (units mm
3). Extra-nodal disease in solid organs and bone
was excluded. All measurements were performed by a radiologist
blinded to the serological biomarker data.
Toxicity recording
Epithelial toxicity was assessed when the patient attended for their
second cycle of chemotherapy. The maximum experience of
vomiting, diarrhoea, stomatitis, inter-current infection and hepa-
totoxicity was graded according to the Common Terminology for
Classification of Adverse Events (CTCAE) version 3.0 (Trotti et al,
2003) and individual grades summed to give an overall subjective
toxicity score. Multifactorial symptoms of nausea and constipation
were not included in the determination of the epithelial toxicity
score, as it can be difficult to attribute these symptoms directly to
epithelial damage. Nausea following chemotherapy may be
initiated by cerebral signalling, and constipation result from
changes to autonomic control of intestinal motility.
Statistics
Statistical analysis was performed using GraphPad Prism version
5.02 for Windows, (GraphPad Software, San Diego, CA, USA,
www.graphpad.com) and probability values of Pp0.05 considered
significant throughout. As the biomarkers were positively skewed,
non-parametric tests were used to satisfy the assumptions of
variance between sample groups. Differences between groups were
tested using Mann–Whitney (M–W) U-test if comparing two
groups or Kruskal–Wallis (K–W) (followed by Dunn’s post hoc
test if significant) if comparing more than two groups. Relation-
ships were examined using the non-parametric Spearman’s rho
bivariate correlation with a two-tailed test for significance. The
Wilcoxin signed test (WST) was used to assess whether changes in
biomarkers following chemotherapy were significantly different
from 0%. The area under the curve (AUC) was calculated using the
trapezoid method. In the absence of pre-existing data, no formal
statistical power calculations were performed.
RESULTS
Utility of circulating nDNA as a biomarker in lymphoma
Baseline levels of nDNA were significantly higher in the 49 patients
with lymphoma (geometric mean 1.58) compared with 61 healthy
volunteers (geometric mean 0.33; K–W Po0.001) and 193 patients
with metastatic carcinomas (small cell lung cancer (n¼67), non-
small cell lung cancer (n¼35) or colorectal cancer (n¼80)
(geometric mean 0.94; K–W Po0.05 see Figure 2A). No
statistically significant relationship was found between lymphoma
histology and baseline nDNA levels (K–W P¼0.99) although the
patients with the four highest values all had DLBCL. No stage-
related trend in baseline nDNA was identified, there was no
difference between patients with/without ‘B’ symptoms (defined as
weight loss 410% of baseline, drenching night sweats or
unexplained fevers 4381C; see Table 2) and no correlation with
LDH levels was seen (R¼0.26). Baseline levels of nDNA did not
correlate with baseline nodal tumour burden using 2D or
volumetric measurements.
Prognostic significance of baseline circulating nDNA
In the DLBCL cohort, disease progression occurred in nine
patients with a median time to progression of 115 days (range
10–277). The median follow-up in non-progressors was 517 days
(range 274–851). Baseline nDNA levels were significantly higher in
progressors (geometric mean 3.62, range 0.50–11.65) compared
with non-progressors (geometric mean 1.0, range 0.06–21.5;
Po0.05). No progression was seen in patients with nDNA levels
below the median observed in healthy subjects (nDNAo0.3). In
patients with levels above the maximum observed in healthy
subjects (nDNA 42.9; n¼11), the median PFS was 83 days (log-
rank; Po0.001) and five patients died with a median OS of
63 days; Po0.05) (Figure 2B). There was no significant difference
between baseline LDH levels in progressors/non-progressors
with DLBCL (geometric mean 598Uml
–1 in progressors vs
681Uml
–1 in non-progressors (P¼0.37).
In the patients with FL, 5 of 10 patients progressed with a median
time to progression of 295 days (range 147–627) and a median PFS
in the remainder of 707 days (range 493–8570). There was no
difference between the baseline levels of nDNA in progressors
(geometric mean 1.37) vs non-progressors (geometric mean 2.55).
Only one patient with HL progressed and subsequently died; prog-
nostic outcome analysis was not therefore performed in this cohort.
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Figure 2 (A) Baseline levels of nDNA in patients with lymphoma
compared with patients with carcinoma and healthy volunteers
(*significantly different from patients with lymphoma Po0.05;.
***significantly different from patients with lymphoma Po0.001). (B)
Prognostic impact of baseline nDNA in patients with diffuse large
B-cell non-Hodgkin lymphoma shown by Kaplan–Meier curve for
progression-free survival.
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In patients with HL, nDNA levels had decreased by 48h following
therapy. By day 15, levels were similar to healthy controls (0.24 vs
0.29; M–W NS with mean change of  2.86, range  9.142 to 0.028;
WST Po0.001) (Figure 3).
In patients with DLBCL, nDNA levels did not decrease until day
8 (Figure 3) (mean change  3.64, range  20.01 to 1.62; WST
Po0.01). Nucleosomal DNA levels were lowest at this point,
significantly lower than baseline and no longer significantly
elevated compared with healthy controls (0.32 vs 0.29 M–W NS).
Initial decreases in nDNA were observed following therapy in all
patients with elevated levels, however, in those who subsequently
progressed, significantly higher levels of nDNA (geometric means
1.58 vs 0.15; Po0.01) were seen by the end of therapy.
In patients with FL, nDNA levels changed more gradually during
the first three weeks of treatment. Nucleosomal DNA levels were
declining by day 3 (Figure 3), a decline sustained throughout the
first cycle (mean change at day 22  1.53 (range  8.73 to 1.49);
WST P¼0.23). However, in contrast to HL and DLBCL, these
changes from baseline did not reach statistical significance and
levels of nDNA at day 22 remained elevated compared with healthy
controls (geometric means baseline 1.87; day 22 0.95; controls 0.29;
K–WPo0.005). Patients with FL where the nDNA levels failed to
fall during the first week of therapy had a significantly worse
outcome with median PFS of 405 days, while only one patient with
a falling nDNA at day 8 had progressed with a median follow-up of
658 days (Po0.05; Supplementary Figure 1).
Analyses were performed to assess whether early changes in nDNA
levels following treatment could predict subsequent radiological
response to therapy. Overall, 26 patients had evaluable CT exam-
inations at baseline and after therapy (Supplementary Table 1).
Levels of nDNA during the first week of therapy (assessed by the
AUC days 1–8) correlated strongly with initial nodal tumour
burden measured in both 2-D and volume (R¼0.53 and 0.49,
respectively; Po0.01), however, there was no statistically signifi-
cant relationship between early changes in nDNA and changes in
tumour volume on completion of therapy.
Taken together, these results suggest that circulating nDNA
levels may have utility as a pharmacodynamic biomarker based on
the rapid decreases in nDNA levels observed following therapy.
Patients with DLBCL/FL and persistent elevation or rising levels in
during therapy had a poorer outcome.
Utility of circulating CK18 as an epithelial toxicity
biomarker
Baseline levels of circulating CK18 in patients with lymphoma
(geometric mean 348Ul
–1) were no greater than observed in
healthy subjects (geometric mean 347Ul
–1) and were significantly
lower than patients with epithelial cancers (geometric mean
712Ul
–1, Po0.001).
Following therapy, CK18 increases peaked at day 3 (HL, mean
change þ33%, range  17 to 113%; DLBCL mean change þ33%,
Table 2 Baseline levels of circulating biomarkers in patients with lymphoma by histology and stage
LDH (Uml
 1) nDNA (OD) CK18 (Ul
 1) FLT3 ligand (pgml
 1)
Histology
Hodgkin lymphoma 403 (236–621) 1.59 (0.06–9.62) 267 (126–470) 96 (40–229)
Follicular lymphoma 404 (301–699) 1.87 (0.57–10.90) 331 (220–580) 153 (90–411)
Diffuse large B-cell lymphoma 626 (310–4030) 1.60 (0.06–21.5) 405 (192–1982) 85 (26–181)
Stage
I 448 (310–653) 2.05 (0.21–8.91) 301 (194–472) 94 (55–134)
II 406 (236–915) 1.56 (0.22–19.05) 338 (193–665) 86 (29–162)
III 650 (360–1331) 2.35 (0.62–21.5) 299 (126–571) 132 (74–229)
IV 555 (270–4030) 1.42 (0.05–11.65) 390 (192–1982) 105 (26–411)
A 454 (236–1311) 1.66 (0.06–21.5) 325 (192–580) 112 (47–411)
B 605 (288–4030) 1.64 (0.06–19.05) 386 (126–1982) 88 (26–229)
Abbreviations: CK18¼cytokeratin 18; LDH¼lactate dehydrogenase; nDNA¼nucleosomal DNA.
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Figure 3 Levels of circulating nDNA in patients with lymphoma treated
with chemotherapy by histological sub-type (samples evaluable at day 1, 3,
8 and 15 for all sub-types and day 22 for FL and DLBCL; dotted line
represents mean value of nDNA in healthy subjects).
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change 14%, range  6 to 64%; DLBCL mean change þ15%, range
 52 to 84%). No significant elevation was seen in CK18 following
chemotherapy in patients with FL (day 3 change þ9%, range  27
to 39% and day 15 change  4%, range  52 to 26%), in keeping
with the lower incidence of epithelial toxicity observed with this
chemotherapy regimen.
In patients with more severe toxicities, higher and more durable
peaks in CK18 were seen following therapy (Figure 4). The change
in CK18 at day 3 gave the greatest power to discriminate patients
experiencing the worst epithelial toxicity. The largest changes in
CK18 were seen in patients with a CTCAE score 43 (mean
increase in CK18 at day 3 for a toxicity score 0¼þ12%; score
1¼ 7%; score 2¼þ3%; score 3¼þ38%; score 4¼þ69% and
score 5¼þ73%). This showed significant differences with a mean
change in CK18 of 62% in patients with toxicity score X3( n¼9)
compared with 12% in patients with toxicity score o3( n¼37;
M–WPo0.005) with an estimated AUC for the receiver operating
characteristics (ROCs) curve to detect an epithelial toxicity CTCAE
score of X3 of 0.85 (Po0.005). These data suggest that CK18 can
be used to predict epithelial toxicity in patients with lymphoma.
Utility of FLT3 ligand as a biomarker of myelosuppression
FLT3 ligand was evaluable in 43 patients (10 HL, 10 FL and 23
DLBCL). Baseline levels were low for all three lymphoma types,
although higher levels were seen in FL than DLBCL. There was no
significant difference between patients with documented bone
marrow involvement and those without (geometric mean involved
115pgml
–1 (range 26–411pgml
–1) vs uninvolved 90pgml
–1
(range 29–229pgml
–1)).
In patients with HL treated with AVBD, an elevation in FLT3
ligand was seen by day 3 (mean change þ166%, range þ46 to
356%), which resolved by day 15 (mean change  2%, range  40 to
36%). In patients with DLBCL, increases in FLT3 ligand did not
occur until day 8 (mean change þ261%, range 16 to 796%), and
while in most was resolving by day 22, some patients had
persistent elevations (mean change þ92%, range  11 to 1280%).
In patients with FL, smaller elevations were seen compared with
other lymphoma subtypes, in keeping with the lower myelo-
suppressive potential of R-CVP. As in DLBCL maximum elevation
was seen at day 8 (mean change þ57%, range 24–111%) with
resolution by day 22 (mean change þ3%, range  54 to 51%).
The correlation of increases in FLT3 ligand at day 8 with
myelosuppression was assessed in all 43 patients, and a significant
correlation with neutropenia (assessed at day 15) was observed
(R¼ 0.34; Po0.05). Nine patients (21%) developed neutropenic
sepsis (NPS) at some point during treatment. These patients had
significantly higher increases in FLT3 ligand at day 8 of their first
cycle of chemotherapy (mean 349%, range 111 to 796%) than
patients who did not develop NPS (mean 131%, range  13 to
482%), (Figure 5A). There was no difference between the nadir
neutrophil count in the two groups (mean 5.9, range 0.3–24.4) in
patients with NPS vs 4.3, range 0.2–13.9 in patients without NPS.
Therefore, measurement of circulating FLT3 ligand at day 8 was a
better predictor of a future episode of NPS then nadir neutrophil
count routinely checked at day 15 (AUC for the ROC curves 0.83
(95% CI 0.70–0.97) for FLT3 ligand vs 0.53 (95% CI 0.34–0.72) for
the neutrophil count, Figure 5B).
DISCUSSION
Improving the efficacy and reducing the toxicity of cancer
treatment are amongst the biggest challenges facing oncologists.
Developing readily measurable biomarkers to accurately predict
and report these endpoints is therefore desirable. The study
presents for the first time, a potential clinical role for a panel of
circulating biomarkers in patients with lymphoma and suggests
the need to further evaluate their utility.
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Figure 5 (A) Comparison of changes in FLT3 ligand at day 8 following
chemotherapy between patients who did and did not experience
neutropenic sepsis (NPS) at any point during treatment. (B) Receiver
operating characteristic curve comparing the utility of FLT3 ligand
measurement at day 8 to neutrophil count at day 15 to predict subsequent
admissions with NPS.
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strongly with PFS and overall survival. Prognosis in this disease
can be estimated by determination of the revised-international
prognostic index, which incorporates both clinical parameters and
LDH (Sehn et al, 2007). This study was not designed or powered to
assess the additional prognostic information given by determina-
tion of nDNA, however, the strong association with poor outcome
in the absence of any observed association with traditional
prognostic parameters (e.g. tumour stage and B symptoms),
suggests a putative role for nDNA as a new independent prognostic
biomarker. This should now be assessed in larger cohorts.
The use of nDNA as a PD biomarker following therapy may give
the most additional clinical utility. In all lymphoma sub-types
rapid falls in nDNA were seen following the initiation of therapy.
Notably, in FL, persistent elevations in nDNA during the first week
of treatment were associated with a significantly shorter time to
progression. These findings suggest that nDNA could be used both
to guide early changes in therapy if an insufficient biomarker
response is observed, and also allow comparison between different
regimens or dosing schedules in early clinical trials. Although
other cell death products have been assessed as PD biomarkers in
lymphoma such as caspase 3 and cytochrome c (Barczyk et al,
2005; Deligezer et al, 2006), nDNA has the advantage that extensive
validation and qualification of this assay has already been
performed in other tumour types (Holdenrieder et al, 2008).
As nDNA is a quasi-quantitative assay (Cummings et al, 2008),
it is difficult to directly compare results between laboratories.
Results in healthy volunteers are consistently and reproducibly low
(Hou et al, 2009). The average values derived in a large cohort of
healthy controls offers a surrogate measure so that other laboratories
can indirectly compare their results with those presented here.
Prediction of toxicity may allow pre-emptive action such as
early clinical review and the potential use of supportive care
medication. We did not examine a detailed temporal relationship
between a rise in CK18 levels and the appearance of epithelial
toxicity. Instead, a maximum peak in CK18 was recorded at day 3
and an obvious difference in CK18 profiles between patients with
and without subsequent toxicity was observed before the clinical
manifestation of toxicity appeared (which typically occurred at
days 7–14). Strategies that increase the dose intensity of
chemotherapy would be facilitated by a measure of epithelial
toxicity and the potential of this approach is currently being tested
in patients with HL treated in a phase I dose-escalation study.
Other biomarkers of small bowel toxicity have been evaluated
including carbon
13-sucrose breath tests, plasma citrulline and
faecal calprotectin and lactoferrin (Lutgens et al, 2005; Hille et al,
2009). However, the clinical utility of these biomarkers has yet to
be fully determined. In addition, CK18 gives a global measure of
epithelial damage, as compared with the specificity to small bowel
damage of the assays described above.
The mechanism of increasing FLT3 ligand in response to bone
marrow stress remains unclear but local release in the bone
marrow, potentially by the stroma, is the leading hypothesis (Prat
et al, 2005). In mice, circulating FLT3 ligand levels at day 3
following radiotherapy predicted the length and depth of
subsequent pancytopenia (Prat et al, 2006). In humans, FLT3
ligand levels rose within 24h of radiotherapy and before the
effect on peripheral blood counts (Bertho et al, 2001). Similarly,
in this study the rise in FLT3 Ligand was observed before the
neutrophil nadir.
An observed increase in FLT3 ligand at day 8 in cycle 1
would potentially allow the use of growth factors or antibiotics
to prevent NPS, even during this cycle of therapy. However, it
may be particularly useful to allow interventions in patients
who first experience NPS in later cycles of therapy (four patients
in this study) or have repeated episodes of NPS (1 patient).
As CK18 and FLT3 ligand appear to measure host toxicity
objectively, potentially they could be used to adjust doses in
an individual patient in order to maximise the therapeutic
index, or in early clinical trials to assess the potential for
future problematic toxicity. The different chemotherapy regimens
examined in this study demonstrated that these biomarkers
are useful in predicting the patients who will experience side
effects both from therapies where relatively high rates of
toxicity can be observed (e.g., ABVD and R-CHOP), but also
from better tolerated regimens (e.g., R-CVP). The utility of these
biomarkers in patients receiving mechanism-based agents is
now being examined.
Our results show the potential utility of a panel of validated
biomarker assays in patients with three sub-types of lymphoma.
The data suggest first that baseline nDNA in DLBCL gives
additional prognostic information over LDH and early changes
during therapy may predict subsequent outcome in FL, second,
that rises in CK18 on chemotherapy give early warning of epithelial
toxicity and third, that substantial elevation in FLT3 ligand
identifies patients at risk of NPS. These results argue for inclusion
of these biomarkers in larger studies testing individualised
treatment strategies.
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